JACC. Advances · 2025
Noninvasive Estimation of Pulmonary Vascular Resistance Using Right Ventricular Outflow Doppler Analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Afonso Luis, Ala Chandra Kanth, Sood Aditya, Adegbala Oluwole, Kahe Farima, Dawdy John, Bell Kendall, Bahar Abdul Rasheed, Blank Nimrod
Аннотация
BACKGROUND: Right heart catheterization (RHC) is the gold standard for measuring pulmonary vascular resistance (PVR). Current noninvasive methods lack accuracy, especially in moderate to severe pulmonary arterial hypertension.
OBJECTIVES: The objective of the study was to develop and validate a novel echocardiographic method for estimating PVR using right ventricular outflow tract Doppler notch analysis.
METHODS: In this prospective study, of 95 patients undergoing RHC, 35 with isolated postcapillary pulmonary hypertension (PVR <2.0 WU) and no discernible Doppler notches were excluded. Of the remaining, 54 patients with interpretable Dopplers were divided into derivation (n = 30) and validation (n = 24) cohorts, all undergoing invasive PVR (iPVR) measurement and echocardiography within 24 hours. Right ventricular outflow tract Doppler, specifically the ratio of notch time (NT) to ejection time, was analyzed to derive a regression equation for non-invasive PVR (niPVR). The model was validated against iPVR and compared with 5 existing methods.
RESULTS: Stepwise linear regression identified the inverse of NT as the strongest predictor of iPVR. After adjusting for heart rate, the model (R2 = 0.93) yielded non-iPVR = 7.1∗(ejection time/NT) - 9.36. Validation against 5 established methods showed superior performance across a PVR range of 2.3 to 14.2 WU, with the highest Pearson correlation (r: 0.76; P < 0.0001; 95% CI: 0.52-0.89). Bland-Altman analysis confirmed superior agreement.
CONCLUSIONS: This novel echocardiographic method offers feasible, rapid, reliable PVR estimation with strong correlation to invasive measurements. Although not a substitute for RHC, this promising preliminary finding from a selective cohort may aid in identifying candidates for invasive testing and guide pulmonary hypertension management. Larger, multicenter validation is warranted.
OBJECTIVES: The objective of the study was to develop and validate a novel echocardiographic method for estimating PVR using right ventricular outflow tract Doppler notch analysis.
METHODS: In this prospective study, of 95 patients undergoing RHC, 35 with isolated postcapillary pulmonary hypertension (PVR <2.0 WU) and no discernible Doppler notches were excluded. Of the remaining, 54 patients with interpretable Dopplers were divided into derivation (n = 30) and validation (n = 24) cohorts, all undergoing invasive PVR (iPVR) measurement and echocardiography within 24 hours. Right ventricular outflow tract Doppler, specifically the ratio of notch time (NT) to ejection time, was analyzed to derive a regression equation for non-invasive PVR (niPVR). The model was validated against iPVR and compared with 5 existing methods.
RESULTS: Stepwise linear regression identified the inverse of NT as the strongest predictor of iPVR. After adjusting for heart rate, the model (R2 = 0.93) yielded non-iPVR = 7.1∗(ejection time/NT) - 9.36. Validation against 5 established methods showed superior performance across a PVR range of 2.3 to 14.2 WU, with the highest Pearson correlation (r: 0.76; P < 0.0001; 95% CI: 0.52-0.89). Bland-Altman analysis confirmed superior agreement.
CONCLUSIONS: This novel echocardiographic method offers feasible, rapid, reliable PVR estimation with strong correlation to invasive measurements. Although not a substitute for RHC, this promising preliminary finding from a selective cohort may aid in identifying candidates for invasive testing and guide pulmonary hypertension management. Larger, multicenter validation is warranted.